vimarsana.com
Home
Live Updates
Onconova Therapeutics Preclinical Narazaciclib Data at SABCS Highlights Differentiated ... | Region : comparemela.com
Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated ... | Region
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors
Related Keywords
Mark Guerin ,
Bruce Mackle ,
Steve Fruchtman ,
Securities Exchange ,
Company Contact ,
Lifesci Advisors ,
Onconova Therapeutics Inc ,
Nasdaq ,
San Antonio Breast Cancer Symposium ,
Chief Executive ,
Onconova Therapeutics ,
Securities Act ,
Securities Exchange Act ,
Private Securities Litigation Reform Act ,
Annual Report ,
Sci Advisors ,
Region ,
comparemela.com © 2020. All Rights Reserved.